Application of astaxanthin in preparation of medicine for treating liver cancer
By sonicating astaxanthin, its inhibitory efficiency on liver cancer cells was improved, and the problem of low efficiency of using astaxanthin alone was solved, achieving efficient and low-toxic liver cancer treatment effect.
Patent Information
- Application Number
- CN202410434064.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-11
- Publication Date
- 2024-12-24
AI Technical Summary
In the prior art, the use of astaxanthin alone has low efficiency in inhibiting liver cancer cells and needs to be combined with other ingredients to effectively inhibit tumors.
Drugs for treating liver cancer were prepared by sonicating astaxanthin. The ultrasonic power was 240-280W, the time was 2-3 seconds, and the number of times was 13-17 times. It was used to prepare inhibitors that inhibit the growth of liver cancer cells as the only activity Ingredients or combined with pharmaceutical excipients.
It significantly improves the inhibitory effect of astaxanthin on liver cancer cells, with an inhibition rate of up to 96.2%, providing new ideas for treating liver cancer and reducing the toxic side effects of chemotherapy.
Smart Images
Figure CN119174748A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to the application of astaxanthin in the preparation of medicines for treating liver cancer. Background Art
[0002] Liver cancer can be divided into two categories: primary and secondary. Primary liver malignant tumors originate from the epithelial or mesenchymal tissue of the liver. The former is called primary liver cancer, which is a common and extremely harmful malignant tumor; the latter is called sarcoma, which is relatively rare. Secondary or metastatic liver cancer refers to malignant tumors originating from multiple organs in the body that invade the liver. It is generally common in liver metastases from malignant tumors of organs such as the stomach, bile duct, pancreas, colorectum, ovary, uterus, lung, and breast. The liver cancer mentioned in daily life mostly refers to primary liver cancer, which generally has pain in the liver area, enlarged liver, and some systemic and digestive tract symptoms, which may be related to cirrhosis, viral hepatitis, and chemical carcinogens such as aflatoxin and environmental factors.
[0003] Treatments for primary liver cancer include: surgical resection, chemotherapy, radiotherapy, etc., but there is still a high recurrence and high metastasis after treatment. Chemotherapy plays an important role in the late treatment of liver cancer. However, long-term chemotherapy can cause tumors to develop drug resistance, resulting in ineffective chemotherapy or poor chemotherapy effects. Moreover, chemotherapy drugs have greater toxic side effects for patients, and long-term chemotherapy is not conducive to the recovery of patients. Therefore, it is urgent to develop new, highly effective and low-toxic anti-liver cancer drugs that can effectively treat liver cancer.
[0004] Astaxanthin is a ketocarotenoid, with the chemical name 3,3′-dihydroxy-4,4′-diketo-β,β′-carotene. It is a red solid powder, fat-soluble, insoluble in water, and soluble in organic solvents. It is widely present in the biological world, especially in the feathers of aquatic animals such as shrimp, crab, fish and birds, and plays a role in color development. Astaxanthin is a chain-breaking antioxidant with extremely strong antioxidant capacity. It can remove nitrogen dioxide, sulfide, disulfide, etc., and can also reduce lipid peroxidation and effectively inhibit lipid peroxidation caused by free radicals. At the same time, it has many physiological effects such as inhibiting tumor occurrence, enhancing immunity, and removing free radicals in the body. In the prior art, astaxanthin needs to cooperate with other components to achieve the effect of inhibiting tumors. The anti-cancer efficiency of astaxanthin alone is not high. Summary of the invention
[0005] The present invention overcomes the defect of low tumor inhibition efficiency of astaxanthin used alone in the prior art, and provides the use of astaxanthin in preparing a medicine for treating liver cancer.
[0006] In order to solve the above technical problems, the present invention adopts the following technical solutions.
[0007] The first aspect of the present invention provides the use of astaxanthin in preparing a drug for treating liver cancer, wherein the astaxanthin is used for preparing the drug for treating liver cancer after being subjected to ultrasonic treatment.
[0008] In some technical solutions of the present invention, the power of the ultrasound is 240-280W.
[0009] In some technical solutions of the present invention, the ultrasonic time is 2-3s.
[0010] In some technical solutions of the present invention, the number of ultrasounds is 13-17 times.
[0011] In some technical solutions of the present invention, after each ultrasound, there is a pause of 3-4 seconds before ultrasound is repeated.
[0012] In some technical solutions of the present invention, the drug is used to prepare an inhibitor for inhibiting the growth and proliferation of liver cancer cells.
[0013] In some technical solutions of the present invention, the liver cancer cells are HepG2 and HuH7 liver cancer cells.
[0014] The second aspect of the present invention provides a liver cancer cell inhibitor, wherein the liver cancer cell inhibitor contains the astaxanthin as the only active ingredient.
[0015] The third invention of the present invention provides a pharmaceutical composition, which comprises the liver cancer cell inhibitor and pharmaceutically acceptable excipients.
[0016] In some technical solutions of the present invention, the content of the liver cancer cell inhibitor in the pharmaceutical composition is 1w%-99w%.
[0017] In some embodiments of the present invention, pharmaceutically acceptable excipients broadly refer to any component other than the active therapeutic ingredient. Excipients can be inert substances, inactive substances and / or non-pharmaceutically active substances. Excipients can be used for various purposes, such as as carriers, vehicles, diluents, tablet adjuvants and / or to improve the administration and / or absorption of active substances.
[0018] In some embodiments of the present invention, the excipient is selected from one or more of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids and release retardants.
[0019] In some embodiments of the present invention, the filler is selected from starch, sucrose, lactose or microcrystalline cellulose; the binder is selected from cellulose derivatives, alginate, gelatin or polyvinyl pyrrolidone; the wetting agent is selected from water, glycerol, ethanol, methylcellulose, sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose or hydroxypropyl methylcellulose; the disintegrant is selected from sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate or sodium bicarbonate; the absorption promoter is a quaternary ammonium compound; the surfactant is selected from cetyl alcohol or sodium lauryl sulfate; the adsorption carrier is selected from kaolin or bentonite; the lubricant is selected from talc, calcium and magnesium stearate, micropowder silica gel or polyethylene glycol; the flavoring agent is selected from sucrose, monosyrup, aromatic syrup, glycerol, sorbitol or mannitol.
[0020] Compared with the prior art, the present invention has the following beneficial effects: in the prior art, astaxanthin needs to be used in combination with other ingredients to achieve the expected treatment of cancer, while in the present invention, it is found that astaxanthin treated with ultrasound can better inhibit the growth and proliferation of liver cancer cells, and its inhibition rate can be as high as 96.2%, indicating that the combination of ultrasound can significantly improve the inhibitory effect of astaxanthin on liver cancer, providing a new idea for the treatment of liver cancer cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is a graph showing the effect of astaxanthin treatment on the growth rate of HepG2 liver cancer cells.
[0022] Figure 2 This is an electron micrograph of HepG2 liver cancer cells treated with the same dose of DMSO as the control group.
[0023] Figure 3 This is an electron micrograph of HepG2 liver cancer cells treated with 300 μM astaxanthin.
[0024] Figure 4 This is an electron micrograph of HepG2 liver cancer cells in 300 μM ultrasonically treated astaxanthin.
[0025] Figure 5 This is a graph showing the effect of astaxanthin treatment on the growth rate of HuH7 liver cancer cells.
[0026] Figure 6 This is an electron micrograph of HuH7 liver cancer cells treated with the same dose of DMSO as the control group.
[0027] Figure 7 This is an electron micrograph of HuH7 liver cancer cells treated with 300 μM astaxanthin.
[0028] Figure 8 Electron micrograph of HuH7 liver cancer cells in 300 μM ultrasonically treated astaxanthin. DETAILED DESCRIPTION
[0029] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0030] Experimental Materials:
[0031] Astaxanthin was purchased from Sigma with the product number SML0982-50MG.
[0032] HepG2 and HuH7 liver cancer cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences.
[0033] The CCK8 kit was purchased from Solarbio with the brand number CA1210.
[0034] Astaxanthin is a ketocarotenoid, with the chemical name 3,3′-dihydroxy-4,4′-diketo-β,β′-carotene. It is a red solid powder, fat-soluble, insoluble in water, and soluble in organic solvents. Astaxanthin has many physiological effects, such as inhibiting tumor occurrence, enhancing immunity, and removing free radicals in the body. However, in the prior art, astaxanthin needs to be combined with other components to achieve a better tumor inhibition effect, and the anti-cancer efficiency of astaxanthin alone is not high. The present invention provides the use of astaxanthin in the preparation of a drug for the treatment of liver cancer, and astaxanthin is used to prepare a drug for the treatment of liver cancer after ultrasonic treatment. It was found through experiments that the ultrasonically treated astaxanthin has a higher inhibition efficiency on liver cancer cells, which can reach up to 96.2%. Compared with the non-ultrasonicated group, its inhibition rate has increased by about 20%.
[0035] Example 1: Effect of ultrasonic treatment of astaxanthin on HepG2 liver cancer cells
[0036] 1. HepG2 liver cancer cell culture
[0037] 8000 HepG2 liver cancer cells were inoculated into 96-well plates containing 100 μL of DMEM medium in each well and incubated at 37°C for 24 h for the cells to adhere to the plate before use.
[0038] 2. Experimental Design
[0039] Remove the culture medium from the cultured HepG2 liver cancer cells and add fresh culture medium again, 100 μL culture medium per well. Set up a control group, astaxanthin group, and ultrasound group, and treat the HepG2 liver cancer cells that have been replaced with fresh culture medium respectively. The setting methods of each group are as follows:
[0040] Preparation of DMSO solution containing astaxanthin: adding astaxanthin into DMSO solvent to prepare DMSO solutions with astaxanthin concentrations of 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, and 300 μM;
[0041] Control group: 2 μL DMSO solvent was added to each well of a 96-well plate of HepG2 liver cancer cells, and CCK8 reagent was added after culturing for 24 hours (refer to the CCK8 kit manual for specific usage), and the cells were cultured in an incubator for another 3 hours, and the absorbance was measured at 450 nm using an ELISA reader;
[0042] Astaxanthin group: 2 μL of DMSO solution containing astaxanthin of different concentrations was added to each well of a 96-well plate of HepG2 liver cancer cells in a total volume of 100 μL of culture medium. After culturing for 24 h, 10 μL of CCK8 reagent was added. The cells were cultured in an incubator for another 3 h, and the absorbance was measured at 450 nm using an ELISA reader.
[0043] Ultrasonic group: 2 μL of DMSO solution containing different concentrations of astaxanthin was placed in a SONICS VC800 ultrasonic disruptor, and ultrasonicated at an intensity of 30% (i.e., a power of 240 W), ultrasonicated for 2 seconds each time, paused for 3 seconds and then ultrasonicated again, for a total of 15 times, and allowed to stand for 5 minutes after ultrasonication to promote the dissolution of astaxanthin while reducing the heat generated by ultrasound. It was then dropped into a 96-well plate and cultured for 24 hours. CCK8 reagent was then added, and the plate was continued to be cultured in an incubator for 3 hours. The absorbance was measured at 450 nm using a microplate reader; ultrasound was performed using a SONICS VC800 ultrasonic disruptor.
[0044] The inhibition rate of HepG2 liver cancer cells was calculated by the following formula:
[0045] Inhibition rate % = 1- OD value of experimental group / OD value of control group × 100%
[0046] Wherein: The OD value of the experimental group is the absorbance value of the astaxanthin group and the ultrasound group measured at 450nm.
[0047] Example 2: Effect of ultrasonic treatment of astaxanthin on HepG2 liver cancer cells
[0048] 1. HepG2 liver cancer cell culture
[0049] 8000 HepG2 liver cancer cells were inoculated into 96-well plates containing 100 μL of DMEM medium in each well and incubated at 37°C for 24 h for the cells to adhere to the plate before use.
[0050] 2. Experimental design
[0051] Remove the culture medium from the cultured HepG2 liver cancer cells and add fresh culture medium again, 100 μL culture medium per well. Set up a control group, astaxanthin group, and ultrasound group, and treat the HepG2 liver cancer cells that have been replaced with fresh culture medium respectively. The setting methods of each group are as follows:
[0052] Preparation of DMSO solution containing astaxanthin: adding astaxanthin into DMSO solvent to prepare DMSO solutions with astaxanthin concentrations of 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, and 300 μM;
[0053] Control group: 2 μL DMSO solvent was added to each well of a 96-well plate of HepG2 liver cancer cells, and CCK8 reagent was added after culturing for 24 hours (refer to the CCK8 kit manual for specific usage), and the cells were cultured in an incubator for another 3 hours, and the absorbance was measured at 450 nm using an ELISA reader;
[0054] Astaxanthin group: 2 μL of DMSO solution containing astaxanthin of different concentrations was added to each well of a 96-well plate of HepG2 liver cancer cells in a total volume of 100 μL of culture medium. After culturing for 24 h, 10 μL of CCK8 reagent was added. The cells were cultured in an incubator for another 3 h, and the absorbance was measured at 450 nm using an ELISA reader.
[0055] Ultrasonic group: 2 μL of DMSO solution containing different concentrations of astaxanthin was placed in a SONICS VC800 ultrasonic disruptor, and ultrasonicated at an intensity of 25% (i.e., a power of 200 W), ultrasonicated for 3 seconds each time, paused for 4 seconds and then ultrasonicated again, for a total of 17 times, and allowed to stand for 5 minutes after ultrasonication to promote the dissolution of astaxanthin while reducing the heat generated by ultrasound. It was then dropped into a 96-well plate and cultured for 24 hours. CCK8 reagent was then added, and the plates were continued to be cultured in an incubator for 3 hours. The absorbance was measured at 450 nm using a microplate reader; ultrasonication was performed using a SONICS VC800 ultrasonic disruptor.
[0056] The inhibition rate of HepG2 liver cancer cells was calculated by the following formula:
[0057] Inhibition rate % = 1- OD value of experimental group / OD value of control group × 100%
[0058] Wherein: The OD value of the experimental group is the absorbance value of the astaxanthin group and the ultrasound group measured at 450nm.
[0059] Compared with Example 1, the intensity and time of ultrasound in the ultrasound group were adjusted in Example 2. Experiments showed that both the ultrasound groups in Example 1 and Example 2 could achieve good results. The following uses Example 1 as an example to illustrate the effects of different treatment groups on the growth inhibition rate of HepG2 liver cancer cells.
[0060] like Figure 1 As shown in Table 1, it can be seen that ultrasonically treated astaxanthin exhibits a more significant inhibitory effect on liver cancer cells, and when the astaxanthin concentration is 300 μM, the inhibition rate on liver cancer cells is the highest.
[0061] Table 1 HepG2 liver cancer cell growth inhibition rate
[0062]
[0063] like Figure 2 As shown, HepG2 liver cancer cells were treated with 2 μL of DMSO solvent and the cell growth was observed. It was found that 2 μL of DMSO solvent had almost no inhibitory effect on HepG2 liver cancer cells.
[0064] Depend on Figure 3 and Figure 4 It can be seen that when the concentration of astaxanthin is 300μM, it can inhibit the growth of HepG2 liver cancer cells, with an inhibition rate of 77.05%, and astaxanthin is partially precipitated in the culture medium; when the HepG2 liver cancer cells are treated with astaxanthin after ultrasonic treatment, significant growth inhibition is shown, with an inhibition rate of 96.2%, which is higher than that of astaxanthin without ultrasonic treatment, and the precipitated astaxanthin particles are significantly larger than Figure 3 The particle size is smaller.
[0065] In summary, after ultrasonic treatment, the particle size of astaxanthin is smaller and the cell growth inhibition rate is higher, indicating that combining ultrasound can significantly improve the inhibitory effect of astaxanthin on liver cancer.
[0066] Example 3: Effect of ultrasonic treatment of astaxanthin on HuH7 liver cancer cells
[0067] 1. HuH7 liver cancer cell culture
[0068] 8000 HuH7 liver cancer cells were inoculated into each well of a 96-well plate containing 100 μL of DMEM medium and incubated at 37°C for 24 hours for the cells to adhere to the plate before use.
[0069] 2. Experimental Design
[0070] Remove the culture medium from the cultured HuH7 liver cancer cells and add fresh culture medium again, 100 μL culture medium per well. Set up a control group, astaxanthin group, and ultrasound group, and treat the HuH7 liver cancer cells that have been replaced with fresh culture medium respectively. The setting methods of each group are as follows:
[0071] Preparation of DMSO solution containing astaxanthin: Add astaxanthin to DMSO solvent to prepare DMSO solutions with astaxanthin concentrations of 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, and 300 μM.
[0072] Control group: 2 μL DMSO solvent was added to each well of the 96-well plate of HuH7 liver cancer cells, and CCK8 reagent was added after culturing for 24 hours (refer to the instructions of CCK8 kit for specific usage), and the cells were cultured in the incubator for another 3 hours, and the absorbance was measured at 450 nm using a microplate reader;
[0073] Astaxanthin group: 2 μL of DMSO solution containing astaxanthin of different concentrations was added to each well of a 96-well plate of HuH7 liver cancer cells in a total volume of 100 μL of culture medium. After culturing for 24 h, 10 μL of CCK8 reagent was added. The cells were cultured in an incubator for another 3 h, and the absorbance was measured at 450 nm using an enzyme reader.
[0074] Ultrasonic group: 2 μL of DMSO solution containing different concentrations of astaxanthin was placed in a SONICS VC800 ultrasonic disruptor, and ultrasonicated at an intensity of 30% (i.e., a power of 240 W). Each ultrasonication was performed for 2 seconds, and then ultrasonicated again after a pause of 3 seconds, for a total of 15 times. After ultrasonication, the solution was allowed to stand for 5 minutes to promote the dissolution of astaxanthin while reducing the heat generated by the ultrasound. The solution was then dropped into a 96-well plate and cultured for 24 hours. CCK8 reagent was then added, and the solution was continued to be cultured in an incubator for 3 hours. The absorbance was measured at 450 nm using a microplate reader. Ultrasonication was performed using a SONICS VC800 ultrasonic disruptor.
[0075] The inhibition rate of HuH7 liver cancer cells was calculated by the following formula:
[0076] Inhibition rate % = 1- OD value of experimental group / OD value of control group × 100%
[0077] Wherein: The OD value of the experimental group is the absorbance value of the astaxanthin group and the ultrasound group measured at 450nm.
[0078] Example 4: Effect of ultrasonic treatment of astaxanthin on HuH7 liver cancer cells
[0079] 1. HuH7 liver cancer cell culture
[0080] 8000 HuH7 liver cancer cells were inoculated into each well of a 96-well plate containing 100 μL of DMEM medium and incubated at 37°C for 24 hours for the cells to adhere to the plate before use.
[0081] 2. Experimental design
[0082] Remove the culture medium from the cultured HuH7 liver cancer cells and add fresh culture medium again, 100 μL culture medium per well. Set up a control group, astaxanthin group, and ultrasound group to treat the HuH7 liver cancer cells that have been replaced with fresh culture medium. The setting methods of each group are as follows:
[0083] Preparation of DMSO solution containing astaxanthin: Add astaxanthin to DMSO solvent to prepare DMSO solutions with astaxanthin concentrations of 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, and 300 μM.
[0084] Control group: 2 μL DMSO solvent was added to each well of the 96-well plate of HuH7 liver cancer cells, and CCK8 reagent was added after culturing for 24 hours. After further culturing in the incubator for 3 hours, the absorbance was measured at 450 nm using an enzyme reader;
[0085] Astaxanthin group: 2 μL of DMSO solution containing astaxanthin of different concentrations was added to each well of a 96-well plate of HuH7 liver cancer cells in a total volume of 100 μL of culture medium. After culturing for 24 h, 10 μL of CCK8 reagent was added. The cells were cultured in an incubator for another 3 h, and the absorbance was measured at 450 nm using an enzyme reader.
[0086] Ultrasonic group: 2 μL of DMSO solution containing different concentrations of astaxanthin was placed in a SONICS VC800 ultrasonic disruptor, and ultrasonicated at an intensity of 35% (i.e., a power of 280 W), with each ultrasonication for 2 seconds, followed by a pause of 3 seconds before ultrasonication again, for a total of 13 times. After ultrasonication, the solution was allowed to stand for 5 minutes to reduce the heat generated by the ultrasound while promoting the dissolution of astaxanthin. The solution was then dropped into a 96-well plate and cultured for 24 hours. CCK8 reagent was then added, and the solution was continued to be cultured in an incubator for 3 hours. The absorbance was then measured at 450 nm using a microplate reader. Ultrasonication was performed using a SONICS VC800 ultrasonic disruptor.
[0087] The inhibition rate of HuH7 liver cancer cells was calculated by the following formula:
[0088] Inhibition rate % = 1- OD value of experimental group / OD value of control group × 100%
[0089] Wherein: The OD value of the experimental group is the absorbance value of the astaxanthin group and the ultrasound group measured at 450nm.
[0090] Compared with Example 3, the intensity and time of ultrasound in the ultrasound group were adjusted in Example 4. Experiments have shown that both the ultrasound groups in Example 3 and Example 4 can achieve good results. Example 3 is used as an example to illustrate the effects of different treatment groups on the growth inhibition rate of HepG2 liver cancer cells.
[0091] like Figure 5 As shown in Table 2, it can be seen that the ultrasonically treated astaxanthin exhibits a more significant inhibitory effect on liver cancer cells, and when the astaxanthin concentration is 300 μL, the inhibition rate on liver cancer cells is the highest.
[0092] Table 2 HuH7 liver cancer cell growth inhibition rate
[0093]
[0094] like Figure 6 As shown, HuH7 liver cancer cells were treated with 2 μL of DMSO solvent and the cell growth was observed. It was found that 2 μL of DMSO solvent had almost no inhibitory effect on HuH7 liver cancer cells.
[0095] Depend on Figure 7 and Figure 8 It can be seen that when the concentration of astaxanthin is 300μM, it can inhibit the growth of HuH7 liver cancer cells, with an inhibition rate of 76.71%, and astaxanthin is partially precipitated in the culture medium; when HuH7 liver cancer cells are treated with astaxanthin after ultrasonic treatment, significant growth inhibition is shown, with an inhibition rate of 95.63%, and the precipitated astaxanthin particles are significantly larger than Figure 7 The particle size is smaller.
[0096] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0097] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. The use of astaxanthin in the preparation of a drug for treating liver cancer, characterized in that: Astaxanthin is used to prepare drugs for treating liver cancer after ultrasonic treatment.
2. The use according to claim 1, characterized in that The power of the ultrasound is 240-280W.
3. The use according to claim 2, characterized in that The ultrasonic time is 2-3s.
4. The use according to claim 2, characterized in that The number of ultrasounds is 13-17 times.
5. The use according to claim 4, characterized in that After each ultrasound, pause for 3-4 seconds before ultrasound again.
6. The use according to claim 1, characterized in that The medicine is used for preparing an inhibitor for inhibiting the growth and proliferation of liver cancer cells.
7. A liver cancer cell inhibitor, characterized in that The liver cancer cell inhibitor contains the astaxanthin described in claim 1 as the only active ingredient.
8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the liver cancer cell inhibitor according to claim 7 and pharmaceutically acceptable excipients.
9. The pharmaceutical composition according to claim 8, characterized in that In the pharmaceutical composition, the content of the liver cancer cell inhibitor is 1w%-99w%.